The Atrial Fibrillation and Oral anticoagulation/Antiplatelet agents Practices in Low Middle-Income settings
DOI:
https://doi.org/10.14738/aivp.102.11901Keywords:
Oral anticoagulation practice in LMIC, Atrial fibrilationAbstract
Background: Atrial fibrillation (AF) is an arrhythmia which is diagnosed by the finding of irregularly irregular ventricular rhythm without discrete P waves in an electrocardiogram. Atrial fibrillation increases risk for intra-cardiac thrombosis and cerebral vascular event .it is a risk factor for ischemic stroke and affects abouts 33 million people globally and is more common in adults above 65 years. It a common complication among the patients with cardiovascular diseases.
Aim of the study: The aim of this study was to audit the use oral anticoagulation/antiplatelet agents in patients with Atrial Fibrillation at Jakaya Kikwete Cardiac Institute
Material and methods: A retrospective descriptive cross-sectional audit study which was conducted at Jakaya Kikwete cardiac institute among adult patients with a diagnosis atrial fibrillation. Patients were identified in a medpro systems and their age and sex were documented. Cross checking for the record of risk scores and OAC/antiplatelet prescription was done and recoded in a structured questionnaire which was designed to collect the data.
Data analysis: The data entry and analysis were done using statistical package for social sciences (SPSS) version 20.0.
Results
Of 800 patients. 37(4.6%) were found to have a diagnosis of AF. Among patients with AF, females were 19 (51.4%), those aged 18-39 years were 13 (35.1%) same as those aged 40-64 years, 65+ years were 11 (29.7). Based on the structural/none structural diagnosis among patients with AF, 20 (54.0%) were having valvular heart diseases. and the rate of use of oral anticoagulation/antiplatelet agents was 73%. Among those using oral anticoagulation/antiplatelet agents, 24 (88.9%) were using warfarin, 2 (7.4%) NOAC and 1 (3.7%) was using antiplatelet (table 2). In terms of INR checking 24 (64.9%) were checked.
Conclusion and Recommendations
The rate of prescription of OAC were high while that for antiplatelet were low. The rate of INR checking in those who were using warfarin were high but not hundred percent. The documentation of risk scores before the prescription of OAC therapy was not done at all.
We recommend for the good practice and follow the recommendations from ESC guideline 2020, our local protocol and evidence-based practice for the management of atrial fibrillation
References
References
Hermiyanty, Wandira Ayu Bertin DS. a LANGE medical book Diagnosis & Treatment CURRENT Cardiology FIFTH EDITION Michael. Vol. 8, Journal of Chemical Information and Modeling. 2017. 1–58 p.
Krittayaphong R, Rangsin R, Thinkhamrop B, Hurst C, Rattanamongkolgul S, Sripaiboonkij N, et al. Prevalence and associating factors of atrial fibrillation in patients with hypertension: A nation-wide study. BMC Cardiovasc Disord [Internet]. 2016;16(1):1–7. Available from: http://dx.doi.org/10.1186/s12872-016-0232-4
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation. 2014;129(8):837–47.
Hylek EM, Phillips KA, Henault LE, Selby J V, Singer DE. Prevalence of Diagnosed Atrial Fibrillation in Adults. JAMA. 2001;285(18):2370–5.
Chugh SS, Roth GA, Gillum RF, Mensah GA. Global burden of atrial fibrillation in developed and developing nations. Glob Heart 2014;9(1):113–9.
Lowres N, Giskes K, Hespe C, Freedman B. Reducing stroke risk in atrial fibrillation: Adherence to guidelines has improved, but patient persistence with anticoagulant therapy remains suboptimal. Korean Circ J. 2019;49(10):883–907.
Siscovick DS, Barringer TA, Fretts AM, Wu JHY, Lichtenstein AH, Costello RB, et al. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory from the American Heart Association. Circulation. 2017;135(15):e867–84.
Voskoboinik A, Kalman JM, Silva A De, Nicholls T, Costello B, Nanayakkara S, et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N Engl J Med. 2020;382(1):20–8.
Task A, Members F, Kirchhof P, Uk C, Uk DK, Uk BC, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS The Task Force for the management of atrial fibrillation of the European Society of Cardiology ( ESC ) Developed with the special contribution of the Europ. Eur Hear J. 2016;37:2893–962.
Stambler BS, Ngunga LM. Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options. Int J Gen Med. 2015;8:231–42.
Eacts CS, Germany CH, Rosenhek R, France EL, Rodriguez D, Tornos P, et al. 2017 ESC / EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology ( ESC ) and the European. 2017. 2739–2791 p.
Bhalia S, Pallangyo P, Dalidali A, Salum S, Kawajika R, Kajuna E, et al. Burden and correlates of atrial fibrillation among hypertensive patients attending a tertiary hospital in Tanzania. BMC Cardiovasc Disord. 2020;20(1):235.
Task A, Members F, Knuuti J, Wijns W, Chairperson I, Capodanno D, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic. Eur Heart J. 2019;425(00):1–71.
Hindricks G, Potpara T, Dagres N, Bax JJ, Boriani G, Dan GA, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498.
Poller L, Aronow WS, Karalis DG, Chandrasekaran K, Mintz GS, Petersen P, et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1991;325:129–32.
Resnicow K, McMaster F, Rollnick S, Heather N, Gold R, Hall W, et al. Motivational Interviewing: moving from why to how with autonomy support. Int J Behav Nutr Phys Act [Internet]. 2012;9(1):19. Available from: http://ijbnpa.biomedcentral.com/articles/10.1186/1479-5868-9-19
Hacke W, Ph D, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. n engl j med. 2011;365(10):883–91.
Hylek EM, Hanna M, Al-khalidi HR, Ph D, Ansell J, Atar D, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. n engl j med. 2011;365(11):981–92.
Friberg L, Rosenqvist M, Lip GYH. Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the swedish atrial fibrillation cohort study. Circulation. 2012;125(19):2298–307.
Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Phil D, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013;369(22):2093–104.
Eikelboom J, Oldgren J, Ph D, Parekh A, Pogue J, Sc M, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361(12):1139–51.
Brieger D, Amerena J, Attia J, Bajorek B, Chan KH, Connell C, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Hear Lung Circ. 2018;27(10):1209–66.
Tze-Fan Chao M, Chern-En Chiang M, Yenn-Jiang Lin M, Shih-Lin Chang M, Li-Wei Lo M, Yu-Feng Hu M, et al. Evolving Changes of the Use of Oral Anticoagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan. Circ AHA. 2018;(138):1485–7.
Shavadia J, Yonga G, Mwanzi S, Jinah A, Moriasi A, Otieno H. Clinical characteristics and outcomes of atrial fibrillation and flutter at the Aga Khan University Hospital, Nairobi. Cardiovasc J Afr. 2013;24(2):6–9.
Bai Y, Wang YL, Shantsila A, Lip GYH. The Global Burden of Atrial Fibrillation and Stroke: A Systematic Review of the Clinical Epidemiology of Atrial Fibrillation in Asia. Chest. 2017;152,(4):810–820.
Lee S-R, Choi E-K, Han K-D, Cha M-J, Oh S, Y. G, et al. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants : A nationwide population-based study. PLOS ONE | www.plosone.org. 2017;1–14.
Mrcp MBP, Mpharm JH. Dawn of the direct-acting oral anticoagulants : trends in oral anticoagulant prescribing in Wales 2009 – 2015. J Clin Pharm Ther. 2017;(42):132–4.
Junya Zhu, PhD GCA. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017. Pharmacotherapy. 2018;38(9):139–48.
Urbaniak AM, Strøm BO, Krontveit R, Svanqvist KH. Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012–2015: A Study from the Norwegian Prescription Database. Drugs and Aging. 2017;34:635–645.
Singer DE, O’Brien EC, Peterson ED, Piccini JP, Piccini JP. Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J [Internet]. 2017;189:40–7. Available from: http://dx.doi.org/10.1016/j.ahj.2017.03.024
Robson J, Dostal I, Mathur R, Sohanpal R, Hull S, Antoniou S. Improving anticoagulation in atrial fibrillation : observational study in three primary care trusts. Br J ofGeneralPractic. 2014;(January):275–81.
Fibrillation NA. Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With. Chest. 2015;148(1):62–72.
Joung B, Lee JM, Lee KH, Kim T, Choi E, Lim W, et al. 2018 Korean Guideline of Atrial Fibrillation Management. Vol. 48. 2018. 1033–1080 p.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 SAMWEL JACOB RWEYEMAMU, DR. Mutagaywa, DR. Naizihijwa , DR.Waane, DR. Kisenge
This work is licensed under a Creative Commons Attribution 4.0 International License.
